The FDA announced its decision regarding the Advisory Committee for Capricor Therapeutics' drug, deramiocel, on June 26, 2025.
2 reports, 1 independent
Updated Jun 26
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA announced its decision regarding the Advisory Committee for Capricor Therapeutics' drug, deramiocel, on June 26, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Capricor Therapeutics (United States)
company in Beverly Hills, United States
Nothing else this week.
- FDA
Related events
- PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
- The FDA indicated on June 25, 2025, that an Advisory Committee (AdCom) was not necessary for a specific review.
Coverage
Newest first; wire copies grouped- manilatimes.net
- Unknown outlet